Skip to main content

The Globe and Mail

CanniMed files lawsuit over Aurora’s hostile bid

Cannabis seedlings at the Aurora Cannabis facility in Montreal are seen in this file photo.


CanniMed Therapeutics Inc. is suing a former and a current director, its largest investors, Aurora Cannabis Inc. and Canaccord Genuity Group Inc. for allegedly misusing its confidential information and conspiring to engineer Aurora's hostile takeover of CanniMed.

The lawsuit was filed late on Friday in an Ontario court, but hasn't yet been served. The allegations in the filing echo claims made by CanniMed last month to the press and at a hearing contesting Aurora's unsolicited offer to buy the Saskatoon company.

CanniMed is claiming that these people and their companies misused its confidential information and that some breached their fiduciary duty to CanniMed, among other charges, according to the statement of claim.

Story continues below advertisement

The company is seeking damages of $725-million. CanniMed says that the defendants' actions have put a ceiling on the company's stock and prevented it from pursuing other deals.

"These bad actors, working in concert, have done the company and other shareholders a significant disservice and we can't let them get away with this," Brent Zettl, chief executive officer at CanniMed, said in a statement.

A spokesperson for Canaccord didn't immediately respond to a request for comment late Friday.

Cam Battley, chief corporate officer at Aurora, called the lawsuit "frivolous" and said that Aurora didn't receive any information about CanniMed that was material or confidential.

"CanniMed had an army of lawyers trying to prove their case to the regulators and they failed," he said by phone, referring to last month's joint hearing over Aurora's hostile bid. "And now they're trying to achieve by lawsuit what they weren't able to achieve with the regulators."

Report an error Editorial code of conduct Licensing Options
Tickers mentioned in this story
Unchecking box will stop auto data updates
As of December 20, 2017, we have temporarily removed commenting from our articles as we switch to a new provider. We are behind schedule, but we are still working hard to bring you a new commenting system as soon as possible. If you are looking to give feedback on our new site, please send it along to If you want to write a letter to the editor, please forward to